Aptorum lists on Euronext.

Darren Lui, President and Executive Director, opens the trading day in Paris.

Aptorum Group Limited specialises in the research and development of therapeutic products in the fields of neurology, infectious diseases, gastroenterology, oncology, and so on.

At the end of 2018, the group had one product in phase I/II clinical development (SACT-1; neuroblastoma treatment) and 6 products in preclinical development (ALS-4, ALS-1, ALS-2, ALS-3, CLS-1 and DOI NLS-2).